Pérez-Hernández María Del Pilar M, Castillo-Chávez Luis M
MP: Lic. Economía. Ph. D. Economía y Gestión de la Innovación y Política Tecnológica. M. Sc. Economía y Gestión del Cambio Tecnológico. Centro de Investigaciones Económicas, Administrativas y Sociales (CIECAS), Instituto Politécnico Nacional (IPN). Ciudad de México, México.
LC: MD. Ph.D.; M.Sc. Ciencias Biológicas. Centro de Investigaciones Económicas, Administrativas y Sociales (CIECAS), Instituto Politécnico Nacional (IPN). Ciudad de México, México.
Rev Salud Publica (Bogota). 2023 Sep 1;25(5):110791. doi: 10.15446/rsap.V25n5.110791. eCollection 2023 Oct.
Vaccines have transformed health globally. The disruption caused by the Covid-19 pan-demic revealed the fragility of healthcare systems around the world. Those countries with capacities in the development and manufacture of vaccines promoted the increase in financing for the development of possible vaccines. In the case of Mexico, once the world leader in vaccine production, it exhibited decades of neglect and little response capacity to meet the needs brought about by the pandemic. This paper analyzes the evolution of the capacities of the vaccine production industry in Mexico. The methodology makes a critical review of the literature regarding the evolution of the productive and technological trajectory of the vaccine industry. The findings point to the fact that the vaccine industry in Mexico, derived from the deterioration of investment in the sector, the lack of organizational flexibility of the public company that produces vaccines, and the absence of public policies, caused the loss of the capacity to generate autonomy in the vaccine manufacturing, it is therefore imperative to review the need to have local capacities for vaccine manufacturing as a strategic area of development for the nation.
疫苗已经在全球范围内改变了健康状况。新冠疫情造成的破坏揭示了世界各地医疗保健系统的脆弱性。那些具备疫苗研发和生产能力的国家推动了对可能的疫苗研发资金投入的增加。就墨西哥而言,该国曾是疫苗生产的全球领先者,但在几十年里却疏于投入,应对疫情带来的需求时反应能力不足。本文分析了墨西哥疫苗生产行业能力的演变。该方法对有关疫苗行业生产和技术轨迹演变的文献进行了批判性审视。研究结果表明,墨西哥的疫苗行业由于该部门投资的减少、生产疫苗的国有企业缺乏组织灵活性以及公共政策的缺失,导致丧失了疫苗制造的自主能力,因此有必要审视将具备本地疫苗制造能力作为国家发展战略领域的必要性。